Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

Launched by SINGAPORE GENERAL HOSPITAL · Jan 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called secukinumab for adults with moderate to severe plaque psoriasis, a skin condition that can cause significant discomfort and impact daily life. The trial aims to explore whether some patients can safely stop this medication after achieving good control of their psoriasis, and how long they can maintain that control without ongoing treatment. By understanding how patients respond after stopping secukinumab, researchers hope to find better and more cost-effective treatment options for managing psoriasis.

To participate in this trial, you must be over 21 years old and have been diagnosed with plaque psoriasis that is moderate to severe. This means your psoriasis affects a significant portion of your body and has been evaluated by a dermatologist. Participants will undergo monitoring during the study, and certain conditions, such as other active infections or specific skin disorders, may prevent you from joining. This trial is not yet recruiting participants, but it represents an important step in finding effective ways to manage psoriasis while considering the costs involved with treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (\>21-year-old).
• • Diagnosed by dermatologist as plague-type PsO.
• * Having moderate to severe plague-type PsO as defined by the following:
• • Psoriasis Area and Severity Index (PASI) ≥12/72,
• • And, investigator Global Assessment Score (IGA) ≥3,
• • And, PsO involving body surface area involvement (BSA) ≥10%
• • And Candidate for phototherapy and/or systemic therapy
• • Topical corticosteroid up to moderate potencies are allowed
• • Able to provide informed consent.
• Exclusion Criteria:
• • Forms of PsO other than plaque-type.
• • Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the investigational product on PsO.
• • Evidence of active tuberculosis or other active infections (like Hepatitis C/B), malignancy; active or known use of other immunosuppressive drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit.
• • Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy
• • History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
• • Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated.
• • History of inflammatory bowel disease.
• • Pregnancy or lactating mothers.
• • As treatment regimen is different, participants with evidence of PsA will be excl